I agree with Mr. Brown. I think it's really important we do this and I'd like to give you my reasons.
We have to look at that decision leading up to the August 26 meeting and at what evidence was weighed, what was included, and what wasn't. I know there was fear of biasing the sample, so they didn't include experts who had actually done the procedure, but we had people who had actively spoken out against it. It was a very limited focus: it was only published papers, and they did not go to the experts. They did not ask for unpublished data. They did not ask how people around the world were doing those procedures, what the safety was, or what the efficacy was.
I think it's important to find out what the doctors doing the follow-up, the neurologists, had to say. There are questions. The MS Society had been asking for $10 million for clinical trials since the spring and have stopped asking for that. There have since been three international conferences on CCSVI at which a lot of science has been presented. I've been to two of those; I chose not to go to the third because it was a week later. The expert panel is meeting for the first time today.
The last point I want to bring up is that we have got to ask questions regarding follow-up care. This is a real issue. We can't have people coming home and not getting treated. I got an e-mail last night from a mother saying they wouldn't look at her son--and then, after going to the college of physicians, being no further ahead.
Those are my reasons.